Get the latest updates on Vikran Engineering IPO allotment date, GMP, and steps to check share allotment status online through BSE, NSE, and Bigshare Services.
A US federal appeals court has ruled that most of President Donald Trump’s global tariffs were imposed illegally, sparking uncertainty over the future of global trade and potential implications for Indian investors.
India’s economy is expected to grow 6.5% in FY26, driven by strong Q1 growth, but tariff tensions pose risks. What does this mean for investors and the Indian stock market?
The US economy has expanded at a faster pace than initially estimated, driven by a pickup in business investment and a boost from trade. What does this mean for Indian investors ahead of the key inflation report?
Groww’s confidential filing for an initial public offering has been approved by SEBI, with the company likely to raise $1 billion and valuing it at around $7 billion.
Vikran Engineering Ltd.’s initial public offering (IPO) has garnered significant interest, subscribing 5.24 times on the second day. The IPO, which consists of a fresh issue of up to Rs 721 crore and an offer for sale of Rs 51 crore, is set to list on the BSE and NSE on September 3.
The proposed merger of Dr. Agarwal Eye Hospital Ltd. with Dr. Agarwal Health Care Ltd. is expected to drive better operational and financial efficiency, enhancing the value of the overall business through unified capital allocation.
Jefferies’ Greed & Fear report warns of 1-1.2% impact on India’s GDP and corporate earnings if US maintains 50% tariff rate, but Indian stock markets remain resilient due to government policy response.
Get the latest updates on the Vikran Engineering IPO, including subscription status, grey market premium (GMP), and listing details. Find out how to invest and what to expect from this IPO.
Anlon Healthcare Ltd.’s initial public offering (IPO) was fully subscribed on the first day of its opening, with retail investors showing strong interest. The IPO, worth Rs 121.03 crore, is expected to bring new opportunities for investors in the pharmaceutical sector.